FH.NE stock is trading at C$0.01 on 03 Feb 2026 during market hours after a one-day drop of 33.33% and volume of 929,483 shares. The NEO-listed Filament Health Corp. (FH.NE) is deep below its 50-day average of C$0.02 and 200-day average of C$0.03, creating a textbook oversold-bounce setup for short-term traders. With EPS at -0.02 and market cap C$3,926,910, we frame a cautious, data-driven bounce plan tied to liquidity, technical resistance, and near-term catalysts.
Market snapshot and intraday action
Filament Health Corp. (FH.NE) opened at C$0.01, with a day low of C$0.005 and day high of C$0.015. Trading volume today is 929,483 versus an average of 4,885,995, so liquidity is thin and price moves can be sharp. The stock sits near its year low of C$0.005 and well below the year high of C$0.07, which matters for stop placement and position sizing.
FH.NE stock technical setup for an oversold bounce
Price is stalled at C$0.01 while the 50-day average is C$0.0231 and the 200-day average is C$0.03302, giving clear resistance levels for a bounce play. Relative volume is 0.19 and ATR is C$0.01, so traders should expect volatile intraday swings. Support sits at C$0.005 and immediate resistance zones are C$0.02 and C$0.033, which map to the 50- and 200-day averages. A decisive move above C$0.02 on higher volume would validate a short-term bounce thesis.
Fundamentals, valuation and risks
Filament Health is a small Healthcare company focused on natural psychedelic drug discovery. Key ratios show EPS -0.02, PE -0.50, price-to-book 1.50, and price-to-sales 12.57, indicating early-stage revenue and negative profitability. Balance-sheet metrics show cash per share 0.0015 and a current ratio 0.44, which highlight liquidity risk. Investors should weigh thin free cash flow and low working capital against speculative upside from IP or licensing deals.
Meyka AI grade and what it means
Meyka AI rates FH.NE with a score of 57.89 out of 100 — Grade C+ with a suggestion: HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. This grade is informational and not financial advice. It flags a speculative name with market-beating upside only if execution or liquidity improves.
Price targets, Meyka AI forecast and probabilities
Meyka AI’s forecast model projects a short-term bounce target of C$0.02 and a medium-term recovery target of C$0.05 versus the current C$0.01, implying upside of +100.00% and +400.00% respectively. Forecasts are model-based projections and not guarantees. Use a scenario approach: conservative scenario targets C$0.015–C$0.02 with tight stops, while a higher-reward scenario targets C$0.05 if volume and corporate catalysts return.
Trading plan, catalysts and checklist
A cautious oversold-bounce trade: size small, set a stop below C$0.005, and target partial exits at C$0.015 and C$0.02. Watch for volume above 1.5M which would validate a stronger move. Catalysts that change the thesis include licensing deals, trial updates, or a financing announcement. Absent positive news, this remains a high-risk equity with potential for rapid declines.
Final Thoughts
Key takeaways: FH.NE stock trades at C$0.01 on 03 Feb 2026 and shows a clear oversold profile on low volume. Short-term technical targets are C$0.015 and C$0.02; resistance at the 50-day (C$0.0231) and 200-day (C$0.03302) moving averages matters for follow-through. Meyka AI’s model projects a conservative bounce to C$0.02 (+100.00%) and a conditional recovery to C$0.05 (+400.00%), but these are model outputs, not guarantees. Trade only with strict risk controls. The stock’s fundamentals show negative EPS and tight liquidity, so any long position should be sized for a high failure rate. Monitor volume, corporate updates, and whether price can clear C$0.02 on expanding liquidity before increasing exposure. Meyka AI provides this as an AI-powered market analysis platform to inform your process, not as investment advice.
FAQs
Is FH.NE stock a buy for an oversold bounce?
FH.NE stock may offer a short-term bounce if volume and buyers return. Size positions small, use stops below C$0.005, and aim for partial exits at C$0.015–C$0.02 given high downside risk.
What are the main risks for Filament Health (FH.NE)?
Main risks include negative EPS (-0.02), low current ratio (0.44), thin liquidity, and reliance on biotech licensing or trial news. A lack of positive catalysts can produce further price declines.
What price targets should traders watch for FH.NE stock?
Watch intraday resistance at C$0.015, short-term target C$0.02, and medium-term target C$0.05 per Meyka AI’s scenario analysis. Targets require higher volume to be credible.
How does sector context affect FH.NE on NEO?
FH.NE sits in Healthcare where one-year performance is negative; sector pressure lowers odds of a sustained rally. Positive clinical or licensing news would be needed to shift sentiment meaningfully.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)